User profiles for "author:Werner Poewe"
Werner PoeweProfessor Neurologie Verified email at i-med.ac.at Cited by 128468 |
MDS clinical diagnostic criteria for Parkinson's disease
RB Postuma, D Berg, M Stern, W Poewe… - Movement …, 2015 - Wiley Online Library
This document presents the Movement Disorder Society Clinical Diagnostic Criteria for
Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use …
Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use …
Parkinson disease
W Poewe, K Seppi, CM Tanner, GM Halliday… - Nature reviews Disease …, 2017 - nature.com
Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …
Clinical diagnostic criteria for dementia associated with Parkinson's disease
Dementia has been increasingly more recognized to be a common feature in patients with
Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of …
Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of …
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
GU Höglinger, G Respondek, M Stamelou… - Movement …, 2017 - Wiley Online Library
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results
CG Goetz, BC Tilley, SR Shaftman… - … : official journal of the …, 2008 - Wiley Online Library
We present a clinimetric assessment of the Movement Disorder Society (MDS)‐sponsored
revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS). The MDS‐UDPRS …
revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS). The MDS‐UDPRS …
[HTML][HTML] A randomized trial of deep-brain stimulation for Parkinson's disease
Background Neurostimulation of the subthalamic nucleus reduces levodopa-related motor
complications in advanced Parkinson's disease. We compared this treatment plus …
complications in advanced Parkinson's disease. We compared this treatment plus …
Second consensus statement on the diagnosis of multiple system atrophy
Background: A consensus conference on multiple system atrophy (MSA) in 1998
established criteria for diagnosis that have been accepted widely. Since then, clinical …
established criteria for diagnosis that have been accepted widely. Since then, clinical …
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on …
Abstract The Movement Disorder Society Task Force for Rating Scales for Parkinson's
disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY …
disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY …
Challenges in the diagnosis of Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease and its
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
[HTML][HTML] Rivastigmine for dementia associated with Parkinson's disease
Background Cholinergic deficits are prominent in patients who have dementia associated
with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor …
with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor …